Popular Trials
Antibody Therapy
Convalescent plasma for Coronavirus
Recruiting0 awardsPhase 2
Chicago, Illinois
Patients who are ill with COVID-19 may benefit from receiving convalescent plasma infusions containing antibodies from donors who have recovered from the disease and are proven to no longer be infected. Given the current public health emergency due to COVID-19, the FDA has recently fast-tracked the use of convalescent plasma. The purpose for this study is to assess if convalescent plasma collected from donors previously infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, can provide clinical benefit to those acutely ill with the virus and to evaluate if such treatment is safe. There will be two arms in the interventional study, where subjects will either be treated with convalescent plasma or fresh frozen plasma in a randomized and blinded manner. As an additional comparison, the clinical course of subjects enrolled during the period of the study who do not receive an alternative treatment for COVID-19 will be assessed.
Tyrosine Kinase Inhibitor
Imatinib for COVID-19
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Popular Filters
Trials for Coronavirus Patients
Neurokinin-1 Receptor Antagonist
Tradipitant for Coronavirus
Recruiting1 awardPhase 3
New York, New York
This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection. On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.
Trials for Coronavirus Infection Patients
Selenium-containing compound
Ebselen for Moderate COVID-19
Recruiting0 awardsPhase 2
New Haven, Connecticut
This trial is testing a possible new medication for people who have a positive PCR test for the novel coronavirus and moderate symptoms of COVID-19. The study is double-blind, meaning that neither the participants nor the researchers will know who is receiving the medication or the placebo until after the study is completed.
Behavioural Intervention
Exercise Therapy for Cancer and COVID-19 Recovery
Recruiting1 awardPhase 1
Basking Ridge, New Jersey
This trial will evaluate the safety of an aerobic exercise therapy program for cancer patients recovering from COVID-19. The therapy being used is a walking program that will be adjusted to match participant fitness levels.
Phase 3 Trials
Neurokinin-1 Receptor Antagonist
Tradipitant for Coronavirus
Recruiting1 awardPhase 3
New York, New York
This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection. On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.
Virus Therapy
DAS181 for Respiratory Infections
Recruiting1 awardPhase 3
Duarte, California
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Cancer Vaccine
IMM-101 Immunization for COVID-19 in Cancer Patients
Recruiting2 awardsPhase 3
Hamilton, Ontario
This trial is testing IMM-101, a new treatment that boosts the immune system, on cancer patients. The goal is to see if it can reduce severe respiratory and COVID-19 infections by helping the body fight off these infections better.
Behavioural Intervention
Low Dose Radiation Therapy for COVID-19
Recruiting2 awardsPhase 3
Atlanta, Georgia
This trial compares low dose whole lung radiation therapy to best supportive care and physician's choice in treating patients with COVID-19 infection. Low dose whole lung radiation therapy may work better in improving patients' clinical status, the radiographic appearance of their lungs, or their laboratory blood tests.
Trials With No Placebo
Procedure
Splenic Ultrasound for Long COVID
Recruiting1 award
Minneapolis, Minnesota
This trial is testing a new treatment for Long COVID using a small device that sends sound waves to the spleen. The goal is to see if this can reduce inflammation and improve symptoms in patients who have had ongoing issues after their initial COVID-19 infection.
Procedure
Ventilation Strategy for Acute Respiratory Distress Syndrome
Recruiting1 award2 criteria
New York, New York
This trial tests if adjusting ventilator settings based on lung measurements can reduce deaths in ARDS patients, including those with COVID-19. The goal is to provide better breathing support without causing more lung damage.
Behavioural Intervention
Tele-Wellness App for Stress and Childhood Development
Recruiting1 award3 criteria
Baltimore, Maryland
This trial will provide FCCH providers and parents with a tele-wellness supported app that will offer self-care and parenting/parent engagement support, as well as gamified learning materials for children in early literacy, math, social-emotional learning, and nutrition.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.